No Decrease in Susceptibility to NVC-422 in Multiple-Passage Studies with Methicillin-Resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli

Antimicrobial Agents and Chemotherapy, 04/26/2012

MICs increased 256–fold for E. coli and 32–fold for P. aeruginosa and S. aureus. Mupirocin, fusidic acid, and retapamulin MICs for MRSA increased 64–, 256–, and 16–fold, respectively. No cross–resistance to NVC–422 was observed with mupirocin–, fusidic acid–, and retapamulin–resistant strains.

Print Article Summary Cat 2 CME Report